ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 006,57
0,87%
Dow Jones
38 760,06
0,13%
DAX
18 575,94
0,86%
Brent Oil
78,19
1,40%
Bitcoin
71 600,01
1,38%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Dyne Therapeutics Inc (DYN)

  7. Dyne Therapeutics Inc (DYN) Actualités

DYN

Dyne Therapeutics (DYN)

Dyne Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DYN
DateHeureSourceTitreSymboleSociété
30/05/202413h30GlobeNewswire Inc.Dyne Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
28/05/202413h30GlobeNewswire Inc.Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:DYNDyne Therapeutics Inc
24/05/202423h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
24/05/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
22/05/202422h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
22/05/202402h39GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
21/05/202400h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
20/05/202422h01GlobeNewswire Inc.Dyne Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202412h30GlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsNASDAQ:DYNDyne Therapeutics Inc
19/05/202414h00GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
02/05/202422h10GlobeNewswire Inc.Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
27/03/202421h05GlobeNewswire Inc.Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerNASDAQ:DYNDyne Therapeutics Inc
27/03/202413h30GlobeNewswire Inc.Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:DYNDyne Therapeutics Inc
25/03/202412h30GlobeNewswire Inc.Dyne Therapeutics Announces CEO TransitionNASDAQ:DYNDyne Therapeutics Inc
13/03/202412h30GlobeNewswire Inc.Dyne Therapeutics to Present at Stifel 2024 Virtual CNS DaysNASDAQ:DYNDyne Therapeutics Inc
05/03/202414h22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:DYNDyne Therapeutics Inc
05/03/202413h40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DYNDyne Therapeutics Inc
05/03/202413h35Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DYNDyne Therapeutics Inc
05/03/202413h30GlobeNewswire Inc.Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
14/02/202422h15GlobeNewswire Inc.Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific ConferenceNASDAQ:DYNDyne Therapeutics Inc
14/02/202414h39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DYNDyne Therapeutics Inc
01/02/202413h30GlobeNewswire Inc.Dyne Therapeutics to Present at February Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
19/01/202422h38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:DYNDyne Therapeutics Inc
05/01/202413h30GlobeNewswire Inc.Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
05/01/202404h46GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
05/01/202403h19Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:DYNDyne Therapeutics Inc
03/01/202412h30GlobeNewswire Inc.Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle DiseasesNASDAQ:DYNDyne Therapeutics Inc
02/01/202422h05GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER TrialsNASDAQ:DYNDyne Therapeutics Inc
07/11/202313h30GlobeNewswire Inc.Dyne Therapeutics to Present at November Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
30/10/202312h30GlobeNewswire Inc.Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical MilestonesNASDAQ:DYNDyne Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DYN

Dernières Valeurs Consultées

EU
CDCEX
Caisse Depots et Consign...
COIN
LADYSUSD
Milady
USOTC
FAHE
Fahey Banking (CE)
LSE
11WD
Mdgh 2041
BIT
P1XTL0
NLBNPIT1XTL0 20991231 20...
BIT
I07073
INTESA SANPAOLO
BIT
P1Y8J7
NLBNPIT1Y8J7 20351221 2....
BIT
P20Z27
NLBNPIT20Z27 20241220 5....
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés